Skip to content
NBlaz – Lifestyle
Author:
Leal Therapeutics
Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia
August 17, 2026
Leal Therapeutics Doses First Patient in NeurALS Phase 1/2 Trial of LTX-002 for Amyotrophic Lateral Sclerosis (ALS)
June 23, 2026